Dissecting global protective immune responses to dengue virus
Research type
Research Study
Full title
Dissecting global protective immune responses to dengue virus at single cell resolution
IRAS ID
251118
Contact name
Sarah Teichmann
Contact email
Sponsor organisation
Genome Research Limited, operating as the Wellcome Sanger Institute
Duration of Study in the UK
2 years, 6 months, 30 days
Research summary
Dengue virus (DENV) infects 390 million people each year (Bhatt S. et al. 2013). Tropical countries, including Thailand, are most affected by this mosquito-borne viral illness. The disease greatly impacts the country, both on a social and economic level, leading to increased healthcare spending, and school/ work loss. Currently, there is no specific treatment. The only approved vaccine has limited efficacy and the use in young children is prohibited (Hadinegoro SR. et al. 2015). Therefore, a better vaccine and therapeutic strategies are urgently needed. To better design a vaccine, fundamental knowledge of the natural protective immune response against DENV is critical. By examining blood cells from people who had DENV infection without symptoms (asymptomatic DENV infection), we can gain insights that will inform strategies for effective vaccine design against DENV. We will use a cutting-edge technology, single-cell RNA sequencing, to dissect the global protective immune response to DENV. Ultimately this improved understanding will hopefully lead to
better preventative or therapeutic approaches with DV infection.REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
18/EE/0333
Date of REC Opinion
10 Oct 2018
REC opinion
Unfavourable Opinion